By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MorphoSys AG 

Lena-Christ-Strasse 48

Martinsried  Munich  82152  Germany
Phone: 49-0-89-899-27-0 Fax: 49-0-89-899-27-222



Company News
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014 7:40:19 AM
MorphoSys AG To Receive Milestone Payment For Guselkumab Phase 3 Program 10/23/2014 7:18:57 AM
MorphoSys AG Acquires Lanthipeptide Technology From Lanthio Pharma 10/15/2014 7:31:19 AM
Emergent BioSolutions (EBS), MorphoSys AG Strike Prostate Cancer Pact Worth $183 Million 8/20/2014 6:14:28 AM
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014 7:57:04 AM
MorphoSys AG And Galapagos NV (GLPG.BR) Advance Joint Antibody Program In Inflammatory Diseases Into Preclinical Development 7/23/2014 8:21:22 AM
MorphoSys AG And Merck Serono Enter Strategic Immuno-Oncology Collaboration 6/12/2014 7:45:10 AM
MorphoSys AG To Present At Four Investor Conferences In June 6/2/2014 9:11:50 AM
Annual General Meeting Of MorphoSys AG Approves All Proposals Of The Company's Management 5/23/2014 11:06:44 AM
MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL 5/20/2014 9:43:57 AM